Content and approval process of IMPD in EU MCQs With Answer

Introduction

This quiz collection focuses on the content and approval process of the Investigational Medicinal Product Dossier (IMPD) in the European Union, tailored for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics. The questions cover detailed components of the IMPD — pharmaceutical quality, manufacturing and controls, stability, non-clinical and clinical data, labelling, pharmacovigilance and special considerations for biologicals and imported products. You will also practice regulatory procedures: sponsor responsibilities, competent authority roles, EU submission routes and key documentation such as GMP evidence, QP release and the Investigator’s Brochure. These MCQs are designed to deepen understanding and prepare you for regulatory practice and examinations.

Q1. What are the principal technical sections that must be included in an IMPD for a clinical trial application in the EU?

• Quality (pharmaceutical), Non‑clinical, and Clinical sections
• Marketing authorization dossier, Periodic safety update reports, and Risk Management Plan
• Only quality and manufacturing information; non‑clinical and clinical not required
• Pharmacovigilance only, with no manufacturing details

Correct Answer: Quality (pharmaceutical), Non‑clinical, and Clinical sections

Q2. Who is legally responsible for preparing and submitting the IMPD to the competent authority in the EU?

• The Sponsor of the clinical trial
• The Contract Manufacturing Organization (CMO)
• The Marketing Authorization Holder (MAH) only
• The Clinical Investigator at the trial site

Correct Answer: The Sponsor of the clinical trial

Q3. Which document included in or referenced by the IMPD summarizes existing clinical and non‑clinical safety information for investigators?

• The Investigator’s Brochure (IB)
• The Common Technical Document (CTD) Module 1
• The Marketing Authorization Product Information (SmPC)
• The Periodic Safety Update Report (PSUR)

Correct Answer: The Investigator’s Brochure (IB)

Q4. What evidence of manufacturing compliance is typically required in the IMPD for sites producing the investigational product within the EU?

• A GMP certificate or formal statement of GMP compliance for the manufacturing site
• Only the SOPs for manufacturing, no external certification
• A copy of the clinical protocol instead of GMP evidence
• No manufacturing information is required for clinical trials

Correct Answer: A GMP certificate or formal statement of GMP compliance for the manufacturing site

Q5. Which pharmacovigilance element must the IMPD explicitly describe for the clinical trial?

• A description of the safety reporting procedures including SAE reporting and contact details
• Only the global Risk Management Plan used for marketed products
• Marketing adverse event summaries for unrelated products
• Only the investigator’s contact list without SAE procedures

Correct Answer: A description of the safety reporting procedures including SAE reporting and contact details

Q6. What type of stability data should be provided in the IMPD for trial batches of an IMP?

• Stability data supporting proposed storage conditions and shelf‑life for trial batches
• Only theoretical stability predictions with no experimental data
• Full long‑term commercial stability for ten years is mandatory
• No stability information is required for investigational products

Correct Answer: Stability data supporting proposed storage conditions and shelf‑life for trial batches

Q7. For a biological investigational medicinal product, which additional information is routinely required in the IMPD?

• Detailed characterisation, cell bank and viral safety data specific to biological products
• Only small molecule impurity profiles, no biological characterisation
• Pharmacopoeial monograph text with no product‑specific data
• Marketing authorization of a different biological product is sufficient

Correct Answer: Detailed characterisation, cell bank and viral safety data specific to biological products

Q8. How does the IMPD relate to the Common Technical Document (CTD) format used for Marketing Authorisation applications?

• IMPD follows CTD principles but is adapted and focused on data necessary for investigational use
• IMPD is identical to the full CTD and requires all MA modules
• IMPD is unrelated to CTD and uses a completely different structure defined by each sponsor
• IMPD only contains Module 1 of the CTD and excludes scientific modules

Correct Answer: IMPD follows CTD principles but is adapted and focused on data necessary for investigational use

Q9. Which authority or system receives and assesses the IMPD for multi‑member state clinical trial applications under the EU Clinical Trial Regulation?

• The relevant National Competent Authority via the EU Clinical Trial Portal and Information System (CTIS)
• The European Medicines Agency (EMA) directly issues clinical trial approvals
• The World Health Organization (WHO) central review board
• The local hospital ethics committee only, with no national input

Correct Answer: The relevant National Competent Authority via the EU Clinical Trial Portal and Information System (CTIS)

Q10. What documentation related to batch release is expected for IMPs manufactured in EU member states?

• A Qualified Person (QP) certificate or batch release documentation is required for IMPs manufactured in EU member states
• An investigator signature only, without any QP involvement
• No batch release documentation is required for clinical trial batches
• Only import certificates from non‑EU countries are acceptable

Correct Answer: A Qualified Person (QP) certificate or batch release documentation is required for IMPs manufactured in EU member states

Q11. Which of the following is a mandatory labelling element for an IMP dispensed to trial subjects?

• Trial reference number, batch number, storage conditions and sponsor contact details
• Full manufacturing SOPs printed on the primary label
• Marketing claims and indications from the SmPC
• Only the batch number is required, nothing else

Correct Answer: Trial reference number, batch number, storage conditions and sponsor contact details

Q12. Is information on placebo composition and manufacture required in the IMPD when a placebo is used in the trial?

• Yes — description of placebo composition, manufacture and controls must be included
• No — placebo details are optional and usually omitted
• Only the placebo label is required, not composition
• Placebos are not allowed in EU clinical trials, so no information is needed

Correct Answer: Yes — description of placebo composition, manufacture and controls must be included

Q13. For a first‑in‑human study, which non‑clinical data package is generally expected in the IMPD?

• Pharmacology, ADME, single‑ and repeat‑dose toxicology and safety pharmacology studies as appropriate
• Only in vitro metabolism data; in vivo studies are never required
• Full carcinogenicity and reproductive toxicity data only, no other studies
• No non‑clinical data are required for first‑in‑human trials

Correct Answer: Pharmacology, ADME, single‑ and repeat‑dose toxicology and safety pharmacology studies as appropriate

Q14. When must the sponsor submit an updated IMPD to the competent authority?

• Whenever new safety data, significant manufacturing changes or other substantial amendments arise
• Only at the end of the trial, never during conduct
• Only if the investigator requests additional documents
• Updates are not permitted after initial submission

Correct Answer: Whenever new safety data, significant manufacturing changes or other substantial amendments arise

Q15. Which item is NOT typically a component of an IMPD for a clinical trial?

• Post‑marketing Periodic Safety Update Reports (PSURs) for a marketed product
• Manufacturing process and controls for trial batches
• Non‑clinical pharmacology and toxicology summaries
• Clinical safety and previous human data summaries

Correct Answer: Post‑marketing Periodic Safety Update Reports (PSURs) for a marketed product

Q16. What must a sponsor provide in the IMPD when importing IMP from a non‑EU manufacturer?

• Evidence of GMP compliance for the non‑EU site and documentation for QP release or qualified importation
• Only the shipment invoice, no quality evidence
• A marketing authorization for the product in the country of origin
• Nothing is required for imported IMPs if they are labeled correctly

Correct Answer: Evidence of GMP compliance for the non‑EU site and documentation for QP release or qualified importation

Q17. Through which EU system is a multinational clinical trial application (including IMPD content) submitted under the Clinical Trial Regulation?

• Via the EU Clinical Trial Information System (CTIS) electronic portal
• Directly by email to each national authority with PDFs attached
• Only by postal mail to the European Commission
• Submission to the WHO clinical trials registry instead of EU systems

Correct Answer: Via the EU Clinical Trial Information System (CTIS) electronic portal

Q18. For a multi‑member state trial, which entity coordinates the Part I scientific assessment of the application including the IMPD?

• The Reporting Member State
• The European Court of Auditors
• The Sponsor’s national regulatory office regardless of location
• The Investigational Site’s Ethics Committee only

Correct Answer: The Reporting Member State

Q19. What type of safety analysis must be presented in the IMPD to justify initiation or continuation of a clinical trial?

• A risk‑benefit analysis describing known risks, expected benefits and measures to minimise risks
• Only a marketing justification with commercial projections
• A financial risk assessment for the sponsor’s investment
• Ethical approval letters are sufficient; no scientific safety assessment required

Correct Answer: A risk‑benefit analysis describing known risks, expected benefits and measures to minimise risks

Q20. What role does the Investigator’s Brochure (IB) play within the IMPD package?

• It summarizes preclinical and clinical data to inform investigators and is typically referenced in the IMPD
• It is a manufacturing batch record used to release IMP batches
• It replaces the need for any non‑clinical study reports
• It contains only patient consent forms and no scientific data

Correct Answer: It summarizes preclinical and clinical data to inform investigators and is typically referenced in the IMPD

Download